Laddar...
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
BACKGROUND: Sunitinib prolonged progression-free survival (PFS) versus placebo in patients with metastatic pancreatic neuroendocrine tumors (panNETs) in a phase III trial. The efficacy and safety of sunitinib in patients with panNETs were confirmed in an open-label phase IV trial. OBJECTIVE: To asse...
Sparad:
| I publikationen: | Target Oncol |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer International Publishing
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7810649/ https://ncbi.nlm.nih.gov/pubmed/33411058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00784-0 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|